Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 7:58 PM
Ignite Modification Date: 2025-12-25 @ 5:32 PM
NCT ID: NCT01712204
Description: None
Frequency Threshold: 4
Time Frame: 16 weeks
Study: NCT01712204
Study Brief: A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo Placebo Capsule BID for 16 Weeks Background therapy: Urate-Lowering Therapy (Febuxostat 80 mg QD) None None 1 41 11 41 View
AC-201 AC-201 50mg Capsule BID for 16 Weeks Background therapy: Urate-Lowering Therapy (Febuxostat 80 mg QD) None None 0 41 10 41 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Frequent Gout Attack SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA 16.0 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Blood CPK increased SYSTEMATIC_ASSESSMENT Investigations MedDRA 16.0 View
Hepatic function abnormal SYSTEMATIC_ASSESSMENT Hepatobiliary disorders MedDRA 16.0 View
ALT increased SYSTEMATIC_ASSESSMENT Investigations MedDRA 16.0 View
Tendonitis SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 16.0 View
Renal Impairment SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA 16.0 View
Anemia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA 16.0 View
Nasopharyngitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 16.0 View
Creatinine renal clearance decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA 16.0 View